Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Endogenous Estrogen and Coronary Heart Disease in Women

This study has been completed.
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by:
New York University School of Medicine Identifier:
First received: May 25, 2000
Last updated: December 30, 2015
Last verified: December 2015
To investigate the relation between endogenous levels of estrogen in postmenopausal women and the subsequent development of coronary heart disease.

Cardiovascular Diseases
Coronary Disease
Heart Diseases
Myocardial Infarction

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective

Resource links provided by NLM:

Further study details as provided by New York University School of Medicine:

Study Start Date: April 1994
Primary Completion Date: March 1999 (Final data collection date for primary outcome measure)
Postmenopausal women with coronary heart disease
Postmenopausal women without coronary heart disease
Matched in age to the women with heart disease

Detailed Description:


Studies suggest that estrogen replacement therapy (ERT) lowers the risk of coronary heart disease in postmenopausal women. However, it is not known whether higher endogenous levels of estrogens in the postmenopausal period likewise have a protective effect.


The study used an existing resource of frozen blood samples from a cohort of 7,058 postmenopausal women enrolled between 1985 and 1991 for a study of endogenous hormones and cancer. The cohort was followed up to identify incident cases of coronary heart disease. One hundred thirty cases of coronary heart disease (defined as nonfatal myocardial infarction or death from coronary heart disease) were expected to occur by the end of follow-up. A nested case-control study was conducted in which each case was matched to two women from the cohort who were the same age as the case, donated blood around the same time, and were alive and free of heart disease as of the date of diagnosis of the case. Frozen serum samples from cases and their matched controls were analyzed for total estradiol, bioavailable estradiol (the estradiol fraction not bound to sex hormone binding globulin) estrone, total cholesterol, and high- and low-density lipoprotein cholesterol. Conditional logistic regression for matched sets were employed to determine whether estrogen levels were lower in the cases than their matched controls. The association between estrogen levels and cholesterol fractions was also investigated.


Ages Eligible for Study:   up to 100 Years   (Child, Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
No eligibility criteria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information Identifier: NCT00005446     History of Changes
Other Study ID Numbers: 4375  R29HL052123 
Study First Received: May 25, 2000
Last Updated: December 30, 2015
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cardiovascular Diseases
Heart Diseases
Coronary Disease
Coronary Artery Disease
Vascular Diseases
Arterial Occlusive Diseases
Myocardial Infarction
Pathologic Processes
Myocardial Ischemia
Arteriosclerosis processed this record on October 25, 2016